Výsledky vyhledávání - "Blanka Cieslarová"

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK-954)

Autor: Richard Czerniak, Blanka Cieslarová, Viera Kupčová, Maria Rosario, Ruth Lock, Cheng Dong, George Dukes

Publikováno v: Journal of clinical pharmacology. 62(8)

Felcisetrag (formerly known as TAK-954) is a selective serotonin receptor agonist under investigation for use in patients with postoperative gastrointestinal dysfunction. The safety, tolerability, and pharmacokinetics (PK) of intravenous (i.v.) felci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0dc2f335a01ea9ed7e446e072963c8
https://pubmed.ncbi.nlm.nih.gov/35253917

Zobrazit plný text záznamu

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

Autor: Blanka Cieslarová, Sivi Ouwerkerk-Mahadevan, Atef Halabi, Indra Aerts, Rodica Van Solingen-Ristea, James Witek, Donghan Luo

Publikováno v: The Journal of Clinical Pharmacology. 55:1147-1156

This study aimed to characterize the pharmacokinetic parameters of telaprevir (TVR) in patients with moderate and severe hepatic impairment, measure the unbound (pharmacologically active) plasma concentrations of TVR, and determine if any changes in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abe1d7048eeb484aa3e251c42e3f6dbb
https://doi.org/10.1002/jcph.545

Zobrazit plný text záznamu

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis

Autor: Sophe Ap, Victoria C. Smith, David Gossage, Preeti Lal, Yan Xin, Guang Chen, John S. Sundy, Blanka Cieslarová, Hao Zheng

Publikováno v: Clinical therapeutics. 40(1)

Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b89b3710de33ea9a7d880ed7e2781a2
https://pubmed.ncbi.nlm.nih.gov/29287749

Zobrazit plný text záznamu

Abstract 2770: An open-label comparative study of the pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe hepatic impairment, or normal hepatic function

Autor: John Kemp, Thomas Morris, Blanka Cieslarová, Maria Taboada, Stuart Oliver, Helen Tomkinson

Publikováno v: Cancer Research. 70:2770-2770

Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Zibotentan (ZD4054) is a small-molecule, specific endothelin A (ETA) receptor antagonist being investigated for the treatment of hormone-resistant prostate cancer. Zi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b36fd6fb9775e059facdc111cba0c956
https://doi.org/10.1158/1538-7445.am10-2770

Zobrazit plný text záznamu